Study of meropenem and pralurbactam for certain antibiotic-resistant infections
Treatments studied
Part of Infections clinical trials.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and are currently in the hospital.
- You have a confirmed infection caused by carbapenem-resistant Enterobacteriaceae (a type of bacteria that doesn't respond to many common antibiotics).
- Your infection is one of these types: pneumonia (lung infection), complicated urinary tract infection, complicated abdominal infection, or a bloodstream infection.
- You have not received more than 24 hours of appropriate antibiotics for this infection, or your symptoms have not improved after at least 2 days of treatment.
- You are expected to live for at least another 28 days.
- You are not currently taking more than 3 systemic antibiotics and do not need treatment for longer than 21 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial tests a new antibiotic called YK-1169 compared to a standard antibiotic (ceftazidime-avibactam) in adults with serious lung infections acquired in hospitals or from ventilators. The goal is to see if YK-1169 works as well or better at treating these infections.
This study tests a new combination of two antibiotics (meropenem and pralurbactam) given through an IV to treat serious abdominal infections. It is for adults who need hospital care and might be helped by a stronger infection-fighting drug.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
Hear when a new Hospital-acquired Bacterial Pneumonia (HABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.